Antipsychotic Trials in Schizophrenia


Book Description

Antipsychotic medications are a key treatment for schizophrenia and sales of antipsychotic drugs approach $20 billion per year, with fierce marketing between the makers of the drugs. The U.S. National Institute of Mental Health sponsored the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project to provide independent information about the comparative effectiveness of medications. CATIE was the largest, longest and most comprehensive study of schizophrenia to date. Conducted under rigorous double-blind conditions, Antipsychotic Trials in Schizophrenia presents the definitive archival results of this landmark study. The core of the book consists of chapters focused on specific outcomes that set the CATIE findings in a wider context. Also included are chapters on the design, statistical analyses and implications for researchers, clinicians and policy makers. Psychiatrists, psychiatric researchers, mental health policy makers and those working in pharmaceutical companies will all find this to be essential reading.




First Episode Psychosis


Book Description

The new edition of this popular handbook has been thoroughly updated to include the latest data concerning treatment of first-episode patients. Drawing from their experience, the authors discuss the presentation and assessment of the first psychotic episode and review the appropriate use of antipsychotic agents and psychosocial approaches in effective management.




Treatment–Refractory Schizophrenia


Book Description

Schizophrenia is often associated with an inadequate response to pharmacological and non-pharmacological treatments. How to treat patients who have an unsatisfactory response to anti-psychotics, including clozapine - which is unequivocally the most powerful antipsychotic medication for this recalcitrant population - remains a clinical conundrum. A range of adjunctive medications have been tried with mixed results; there has also been renewed interest in the role of neuromodulatory strategies, electroconvulsive therapy, and cognitive and vocational approaches. Perhaps a bright spot for the future lies in the evolution of pharmacogenetic approaches for individualized care. In this book, leading experts from Europe, Australia and the Americas provide a timely appraisal of treatments for the most severely ill schizophrenia patients. This clinically focused book is informed by the latest research on the neurobiology and treatment of schizophrenia. It is comprehensive in scope, covering current treatment options, various add-on approaches, and a range of psychosocial treatments. The contributors are respected experts who have combined their clinical experience with cutting-edge research to provide readers with authoritative information on fundamental aspects of clinical care for schizophrenia.




Encyclopedia of Psychopharmacology


Book Description

Here is a broad overview of the central topics and issues in psychopharmacology, biological psychiatry and behavioral neurosciences, with information about developments in the field, including novel drugs and technologies. The more than 2000 entries are written by leading experts in pharmacology and psychiatry and comprise in-depth essays, illustrated with full-color figures, and are presented in a lucid style.




Antipsychotic Long-acting Injections


Book Description

Antipsychotic Long-acting Injections (LAIs) were introduced in the 1960s to improve treatment adherence in schizophrenia. Subsequently, first-generation antipsychotic LAIs became widely used in many countries. Since the initial publication of Antipsychotic Long-acting Injections in 2010, new trial data have been published on long-acting injection (LAI) preparations of the drugs Risperidone, Paliperidone, and Olanzapine. Furthermore, a new LAI preparation of the drug Aripiprazole has recently been approved for clinical use in the United States and is likely to be approved in Europe soon. The second edition of this successful book has been fully updated to include this new data, with reference to both observational studies and randomized controlled trials, as well as other new developments in the clinical use of antipsychotic LAIs. New chapters have been added covering the comparison between oral and injectable antipsychotics, Olanzapine LAI, Aripiprazole LAI, and the practicalities of organizing a specialized clinic for long-acting injectable antipsychotics. Existing chapters have also been thoroughly updated to take into account the most recently published research. Antipsychotic Long-acting Injections, Second edition brings together clinical and research findings on LAIs in a comprehensive volume, with chapters written by international experts.




Medical Illness and Schizophrenia


Book Description

Despite growing awareness in the psychiatric community of the multifaceted medical needs of the severely mentally ill, statistics show that as much as 60% of all schizophrenia patients die prematurely from nonpsychiatric medical conditions -- in part because many physicians have not yet recognized how to properly treat common diseases and illnesses within this complex patient population. Medical Illness and Schizophrenia, Second Edition, is the only clinical guide to focus exclusively on the treatment of common medical comorbidities among patients with schizophrenia. Like its best-selling predecessor, the book compiles the latest research and clinical information on integrating medical and psychiatric care for the schizophrenia patient. Twenty-eight physicians and psychiatrists, including editors Jonathan M. Meyer, M.D., and Henry A. Nasrallah, M.D., lend their expertise to this new, expanded edition. In fifteen chapters, this volume covers a wide range of common medical problems -- from metabolic and heart conditions, such as cardiovascular disease, hyperlipidemia, obesity and diabetes, to substance abuse and smoking. Each chapter concludes with "Key Clinical Points" that summarize important concepts and ensure reader retention. Additionally, the second edition includes new chapters that touch on some of the most complex clinical issues in the field of schizophrenia treatment today: Recent trends in the integration of medical and mental healthcare Behavioral treatments for weight loss in persons with schizophrenia Treatment of sexual dysfunction among persons treated for schizophrenia Health outcomes of schizophrenia treatment in children and adolescents Health outcomes of schizophrenia treatment during pregnancy and breastfeeding As the only clinical text of its kind, Medical Illness and Schizophrenia, Second Edition, is an invaluable resource for psychiatrists, nurses, healthcare professionals, and psychiatric and clinical residents. The goal of this text has always been to help clinicians recognize schizophrenia as both a brain disorder and a systemic disease with multiple manifestations that go beyond the obvious psychiatric symptoms -- and thus take a broader approach to treatment of schizophrenia. This new edition is a comprehensive, practical manual that serves as a reference for the medical management of seriously mentally ill patients across the age spectrum in both inpatient and outpatient settings.




Chlorpromazine in Psychiatry


Book Description

The book follows the history of the discovery of drugs that would be used in the treatment of mental illness, in particular schizophrenia by the late 1940s and early 1950s in Switzerland, France, Canada and the USA. The story goes back to 1883 when the chemical progenitors of chlorpromazine were synthesized for use in the blue dye industry in Heidelberg. Then it follows the the development of antihistamines after WW I for the treatment of shock in surgery. In 1950 it was proposed the this class of drugs might be useful in the treatment of mental illness. It is a fascinating history. The history was commissioned bya research group which ask whether the drugs could have been discovered earlier. Could they learn anything from the 90 year history of the development that would help design research projects that could be accelerated if an attempt were made to link the chance discoveries of research more efficiently. Here comes the spoiler: No. It makes the point the apparently that pure research is the basis on which the rest is built.




Search for the Causes of Schizophrenia


Book Description

- The topics covered in the six sections of the book are Epidemiology and Environment, Precursors, Pathophysiological Mechanisms, Genetics, Controversies in Schizophrenia, and Treatment. - Reflects the progress made on Schizophrenia since 1986.




The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia


Book Description

The guideline offers clear, concise, and actionable recommendation statements to help clinicians to incorporate recommendations into clinical practice, with the goal of improving quality of care. Each recommendation is given a rating that reflects the level of confidence that potential benefits of an intervention outweigh potential harms.




Novel Antipsychotic Drugs


Book Description